An interventional study of Exercise program in Psoriatic Arthritis, sponsored by Vastra Gotaland Region. Enrolling by invitation at 2 sites in Sweden. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by Vastra Gotaland Region · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Arthritis, Psoriatic with a site in Sweden — 3 open to participants now, 8 under way, 2 of them phase 3. Arthritis, Psoriatic · Sweden.
Among the 24 studies in Arthritis, Psoriatic with a site in Sweden, this one is the 12th largest by planned enrollment of the 16 interventional ones that give a count, is the only one that started in 2026, is one of 4 with no phase, and was the 22nd registered.
602 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.
Browse Arthritis, Psoriatic studies →3 of the 24 studies in Arthritis, Psoriatic with a site in Sweden are open now. Recruiting first, the newest first:
Region Skane · Sites in Sweden
Ages 18+
Vastra Gotaland Region · Sites in Sweden
Ages 18–80 · Healthy volunteers
A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →
Of the 89 Arthritis, Psoriatic studies recruiting now, 52 (58%) set no upper age limit and 28 (31%) stop at 75 or younger; 12 take children under 18; 14 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 88 is below the median of 145 across 337 interventional studies indexed under Arthritis, Psoriatic.
Median enrollment 276 across the 16 interventional studies, 3,207 across the 8 observational. Of the 14 that completed or were terminated, 7 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 24 have an industry lead sponsor. The 10 most frequent:
Vastra Gotaland Region is the lead sponsor of 276 studies on the registry; 110 are open to participants now.
Vastra Gotaland Region has 5 studies filed under Arthritis, Psoriatic — fewer than ten, so there is no comparison to draw.
2 of the studies in Arthritis, Psoriatic with a site in Sweden that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04929210Janssen Research & Development, LLCA Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease | 2027-04-01 |
| NCT05049798Janssen Pharmaceutica N.V., BelgiumA Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice | 2027-08-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 24 studies in Arthritis, Psoriatic with a site in Sweden, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this randomised controlled trial is to evaluate the effects of a 12-week intervention comprising high-intensity interval aerobic training and strength training on cardiovascular function, metabolic health profile and inflammation in patients with Psoriatic arthritis. A secondary goal is to assess the intervention´s impact on physical fitness, pain, fatigue, and health-related quality of life, and to explore long-term maintenance of exercise following completion of the intervention. We hypothesize that 12 weeks of combined high-intensity interval aerobic training and strength training will improve cardiometabolic health, inflammation, and enhance physical fitness, fatigue, pain and quality of life in Psoriatic arthritis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cardiorespiratory and strength training, 2-3 sessions per week for a total of 12 weeks.
Behavioral: Exercise program
Care as usual, plus individualized counseling for health-promoting physical activity
The exercise program includes two supervised sessions per week combining high-intensity interval training and strength training, plus one additional non-supervised aerobic session. The target of the high intensity intervals is 90%-95% of heart rate maximum. The strength training of major muscle groups includes 2-3 sets of 8-10 repetitions.
Cardiopulmonary function
Change in maximum oxygen uptake (VO2ml/min/kg). Higher value indicate better cardiorespiratory capacity.
Time frame: Baseline and 3 month
Cardiopulmonary function
Change in maximum oxygen uptake (VO2ml/min/kg). Higher value indicate better cardiorespiratory capacity)
Time frame: Baseline and 9 month
Waist circumference
Change in waist circumference (cm) measured with a tape measure midway between the lower rib and iliac crest. A waist measurement of 80 centimeters or more for women and 94 centimeters or more for men indicate increased risk for diseases related to overweight.
Time frame: Baseline and 3 months
Waist circumference
Change in waist circumference (cm) measured with a tape measure midway between the lower rib and iliac crest. A waist measurement of 80 centimeters or more for women and 94 centimeters or more for men indicate increased risk for diseases related to overweight.
Time frame: Baseline and 9 months
Body mass index (BMI)
Change in Body Mass Index (BMI). Weight and height will be combined to report BMI (kg/m2). A higher score indicate higher relative weight.
Time frame: Baseline and 3 months
Body mass index (BMI)
Change in Body Mass Index (BMI). Weight and height will be combined to report BMI (kg/m2). A higher score indicate higher relative weight.
Time frame: Baseline and 9 months
Body composition
Change in total leanmass (%) and fatmass (%) assessed with Bioelectrical Impedance Analysis. Higher value indicate higher total leanmass and fatmass
Time frame: Baseline and 3 months
Body composition
Change in total leanmass (%) and fatmass (%) assessed with Bioelectrical Impedance Analysis. Higher value indicate higher total leanmass and fatmass
Time frame: Baseline and 9 months
Triglycerides
Change in triglycerides (mmol/L)
Time frame: Baseline and 3 months
Triglycerides
Change in triglycerides (mmol/L)
Time frame: Baseline and 9 months
High-density lipoprotein cholesterol (HDL-C)
Change in high-density lipoprotein cholesterol (HDL-C) (mmol/L)
Time frame: Baseline and 3 months
High-density lipoprotein cholesterol (HDL-C)
Change in high-density lipoprotein cholesterol (HDL-C) (mmol/L)
Time frame: Baseline and 9 months
Low-density lipoprotein cholesterol (LDL-C)
Change in low-density lipoprotein cholesterol (LDL-C) (mmol/L)
Time frame: Baseline and 3 months
Low-density lipoprotein cholesterol (LDL-C)
Change in low-density lipoprotein cholesterol (LDL-C) (mmol/L)
Time frame: Baseline and 9 months
Total cholesterol
Change in total cholesterol (mmol/L)
Time frame: Baseline and 3 months
Total cholesterol
Change in total cholesterol (mmol/L)
Time frame: Baseline and 9 months
Glycosylation level of hemoglobin (HbA1c)
Glycosylation level of hemoglobin (HbA1c) (mmol/mol)
Time frame: Baseline and 3 months
Glycosylation level of hemoglobin (HbA1c)
Glycosylation level of hemoglobin (HbA1c) (mmol/mol)
Time frame: Baseline and 9 months
Homeostatic model assessment of insulin resistance (HOMA IR)
Measure of insulin resistance (fasting glucose (mmol/L) and fasting insulin (mIU/ L) will be combined to report Homeostatic model assessment of insulin resistance (HOMA IR).
Time frame: Baseline and 3 monhts
Homeostatic model assessment of insulin resistance (HOMA IR)
Measure of insulin resistance (fasting glucose (mmol/L) and fasting insulin (mIU/ L) will be combined to report Homeostatic model assessment of insulin resistance (HOMA IR).
Time frame: Baseline and 9 months
Erythrocyte Sedimentation Rate (ESR)
Change in level of erytrocyte rate (ESR) (mm/h). Higher score indicate higher degree of inflammation.
Time frame: Baseline and 3 months
Erythrocyte Sedimentation Rate (ESR)
Change in level of erytrocyte rate (ESR) (mm/h). Higher score indicate higher degree of inflammation.
Time frame: Baseline and 9 months
C-Reactive Protein (CRP)
Change in level of of high sensitivity CRP (mg/L). Higher score indicate higher inflammation.
Time frame: Baseline and 3 months
C-Reactive Protein (CRP)
Change in level of of high sensitivity CRP (mg/L). Higher score indicate higher inflammation.
Time frame: Baseline and 9 months
Cytokine levels
Change in inflammatory cytokines such as Interleukin-6 (pg/mL), interleukin-10 (pg/mL), tumour necrosis factor-alpha (pg/mL).
Time frame: Baseline and 3 months
Disease activity
Change in Disease Activity index for PSoriatic Arthritis (DAPSA) score. Calculated by summing 66/68 joints (swollen, tender), patient global assessment (VAS), pain (VAS)and CRP). A higher value indicates a higher disease activity. (Minimum: 0=no disease activity, \>28= high disease activity).
Time frame: Baseline and 3 months
Disease activity
Change in Disease Activity index for PSoriatic Arthritis (DAPSA) score. Calculated by summing 66/68 joints (swollen, tender), patient global assessment (VAS), pain (VAS)and CRP). A higher value indicates a higher disease activity. (Minimum: 0=no disease activity, \>28= high disease activity).
Time frame: Baseline and 9 months
Muscle function lower extremities
Change in the one minute sit-to-stand test (STS). Higher numbers of complete rises indicate better muscle function in lower extremities.
Time frame: Baseline and 3 months
Muscle function lower extremities
Change in the one minute sit-to-stand test (STS). Higher numbers of complete rises indicate better muscle function in lower extremities.
Time frame: Baseline and 9 months
Handgrip strength
Change in grip strength measured with a dynamometer (newton). Higher value indicate better grip strength.
Time frame: Baseline and 3 months
Handgrip strength
Change in grip strength measured with a dynamometer (newton). Higher value indicate better grip strength.
Time frame: Baseline and 9 months
Activity limitations
Change in Health Assessment Questionnaire (HAQ) (0-3). A higher score indicates more activity limitations
Time frame: Baseline and 3 months
Activity limitations
Change in Health Assessment Questionnaire (HAQ) (0-3). A higher score indicates more activity limitations.
Time frame: Baseline and 9 months
Physical function
Change in the Bath Ankylosing Spondylitis Functional Index (BASFI) (0-10). Higher score indicate more physical limitations
Time frame: Baseline and 3 months
Physical function
Change in the Bath Ankylosing Spondylitis Functional Index (BASFI) (0-10). Higher score indicate more physical limitations
Time frame: Baseline and 9 months
Physical activity
Change in self-reported weekly physical activity assessed with the International Physical Activity Questionnaire (IPAQ)-Short Form. Time spent in low, moderate, and vigorous activity is summed within each intensity category. (According to WHO guidelines, ≥150 minutes of moderate or ≥75 minutes of vigorous activity per week qualifies as health-enhancing physical activity).
Time frame: Baseline and 3 months
Physical activity
Change in self-reported weekly physical activity assessed with the International Physical Activity Questionnaire (IPAQ)-Short Form. Time spent in low, moderate, and vigorous activity is summed within each intensity category. (According to WHO guidelines, ≥150 minutes of moderate or ≥75 minutes of vigorous activity per week qualifies as health-enhancing physical activity).
Time frame: Baseline and 9 months
Attitude to exercise
Change in exercise believe assessed with the Exercise Health Beliefs questionnaire (20-100), Higher score represents stronger exercise beliefs.
Time frame: Baseline and 3 months
Attitude to exercise
Change in exercise believe assessed with the Exercise Health Beliefs questionnaire (20-100), Higher score represents stronger exercise beliefs.
Time frame: Baseline and 9 months
Emotional experience of exercise
Change in the Physical Activity Enjoyment Scale (PACES) (18-126). Higher score indicate higher degreee of enjoyment and pleasure related to exercising.
Time frame: Baseline and 3 months
Emotional experience of exercise
Change in the Physical Activity Enjoyment Scale (PACES) (18-126). Higher score indicate higher degreee of enjoyment and pleasure related to exercising.
Time frame: Baseline and 9 months
Sleep quality
Change in Pittsburgh Sleep Quality Index (PSQI) (0-21), Higher score indicate worse sleep quality.
Time frame: Baseline and 3 months
Sleep quality
Change in Pittsburgh Sleep Quality Index (PSQI) (0-21), Higher score indicate worse sleep quality.
Time frame: Baseline and 9 months
Fatigue
Change in The Multiple Fatigue Inventory (MFI-20), 4-20 for each subscale, Higher score indicates a higher degree of fatigue.
Time frame: Baseline and 3 months
Fatigue
Change in The Multiple Fatigue Inventory (MFI-20), 4-20 for each subscale, Higher score indicates a higher degree of fatigue
Time frame: Baseline and 9 months
Pain intensity
Visual Analogue Scale (VAS) (0-100), Higher score indicate worse pain.
Time frame: Baseline and 3 months
Pain intensity
Visual Analogue Scale (VAS) (0-100), Higher score indicate worse pain.
Time frame: Baseline and 9 months
Global health
Change in Visual Analogue Scale (VAS) (0-100), Higher score indicate worse health
Time frame: Baseline and 3 months
Global health
Change in Visual Analogue Scale (VAS) (0-100), Higher score indicate worse health
Time frame: Baseline and 9 months
Health related quality of life
Change in the 36-item Short Form Health Survey (SF-36) questionnare (0-100). A higher score indicate better health related quality of life
Time frame: Baseline and 3 months
Health related quality of life
Change in the 36-item Short Form Health Survey (SF-36) questionnare (0-100). A higher score indicate better health related quality of life
Time frame: Baseline and 9 months
The impact of the disease on quality of life
Change in the Dermatology Life Quality Index (DLQI) (0-30). Higher score indicate worse impairment
Time frame: Baseline and 3 months
The impact of the disease on quality of life
Change in the Dermatology Life Quality Index (DLQI) (0-30). Higher score indicate worse impairment
Time frame: Baseline and 9 months
Mental health
Change in the Hospital and Anxiety Depression Scale (HADS) for anxiety and depression (0-21). A higher score refers to a higher degree of distress.
Time frame: Baseline and 3 months
Mental health
Change in the Hospital and Anxiety Depression Scale (HADS) for anxiety and depression (0-21). A higher score refers to a higher degree of distress.
Time frame: Baseline and 9 months
Disease related symptoms
Patient Global Impression of Change (PGIC) scale (0-7) to adress changes in symtoms. Rating from very much improved (7) to very much worse (1).
Time frame: Baseline and 3 months
Disease related symptoms
Patient Global Impression of Change (PGIC) scale (0-7) to adress changes in symtoms. Rating from very much improved (7) to very much worse (1).
Time frame: Baseline and 9 months
Enthesites
Change in the Entesiter MASES entesit index. Palpation of 13 body sites for tenderness. (0= no tenderness, 1= tenderness presented) Higher scores indicate more widespread/tender enthesitis.
Time frame: Baseline and 3 months
Enthesites
Change in the Entesiter MASES entesit index. Palpation of 13 body sites for tenderness. (0= no tenderness, 1= tenderness presented). Higher scores indicate more widespread/tender enthesitis.
Time frame: Baseline and 9 months
Skin involvement
Skin involvement evaluated using the Body surface area (BSA), percentage of total body surface affected by lesions.
Time frame: Baseline and 3 months
Skin involvement
Skin involvement evaluated using the Body surface area (BSA), percentage of total body surface affected by lesions.
Time frame: Baseline and 9 months
Plan to share: Yes — Individual participant data (IPD) that underlie results in a publication are available from the principal investigator (P.I.) on reasonable request. Access will be determined based on reasonable request and in accordance with the ethical approval
Time frame: The data will become available as following, starting 6 months after publication and end 5 years after publication.
Access criteria: The requests will be reviewed by the P.I. and the steering committee. Study plans on meta-analyses generating new knowledge on exercise in persons with rheumatic diseases will be approved.
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Dec 2027, 23 months after the start.
Of 67 non-industry interventional studies with no phase under Arthritis, Psoriatic, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 43. This study's planned 23 months is below that.
Counting every sponsor, half of 72 studies reached it within 31 months; a quarter within 13 and three quarters within 44.
Start moved once since we started tracking on Sep 25, 2026: Feb 2026 → Jan 2026, on Oct 23, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.